Peng Cheng

ORCID: 0000-0003-4807-7018
Publications
Citations
Views
---
Saved
---
About
Contact & Profiles
Research Areas
  • vaccines and immunoinformatics approaches
  • Tuberculosis Research and Epidemiology
  • Immunotherapy and Immune Responses
  • SARS-CoV-2 and COVID-19 Research
  • Monoclonal and Polyclonal Antibodies Research
  • Pneumonia and Respiratory Infections
  • Immune responses and vaccinations
  • Vascular anomalies and interventions
  • COVID-19 Clinical Research Studies
  • Renal and Vascular Pathologies
  • Acute Myeloid Leukemia Research
  • Sinusitis and nasal conditions
  • Salivary Gland Tumors Diagnosis and Treatment
  • Graphene and Nanomaterials Applications
  • Allergic Rhinitis and Sensitization
  • Family and Disability Support Research
  • Extracellular vesicles in disease
  • Head and Neck Surgical Oncology
  • Ear and Head Tumors
  • Venous Thromboembolism Diagnosis and Management
  • Mycobacterium research and diagnosis
  • Pneumocystis jirovecii pneumonia detection and treatment
  • Orthopedic Infections and Treatments
  • T-cell and Retrovirus Studies
  • Acute Lymphoblastic Leukemia research

Chinese PLA General Hospital
2022-2025

Ningbo First Hospital
2024

Ningbo University
2024

Hebei North University
2022-2024

Shanghai Changzheng Hospital
2023

Civitan International
2011

Greenwood Genetic Center
2011

University of Alabama at Birmingham
2011

Baylor College of Medicine
2011

University of South Florida
2011

Background With the increasing incidence of tuberculosis (TB) and shortcomings existing TB vaccines to prevent in adults, new need be developed address complex epidemic. Method The dominant epitopes were screened from antigens construct a novel epitope vaccine termed HP13138PB. immune properties, structure, function HP13138PB predicted analyzed with bioinformatics immunoinformatics. Then, responses induced by confirmed enzyme-linked immunospot assay (ELISPOT) Th1/Th2/Th17 multi-cytokine...

10.3389/fimmu.2023.1102578 article EN cc-by Frontiers in Immunology 2023-01-27

Background: Latent tuberculosis infection (LTBI) is the primary source of active (ATB), but a preventive vaccine against LTBI lacking. Methods: In this study, dominant helper T lymphocyte (HTL), cytotoxic (CTL), and B-cell epitopes were identified from nine antigens related to regions difference (RDs). These used construct novel multiepitope (MEV) based on their antigenicity, immunogenicity, sensitization, toxicity. The immunological characteristics MEV analyzed with immunoinformatics...

10.3390/vaccines11040856 article EN cc-by Vaccines 2023-04-17

Abstract Background Diagnosing latent tuberculosis (TB) infection (LTBI) and active TB (ATB) is crucial for preventing disease progression transmission. However, current diagnostic tests have limitations in terms of accuracy sensitivity, making it challenging to diagnose these different states. Therefore, this study intends develop a promising biomarker LTBI ATB diagnosis overcome the tests. Methods We developed novel multiepitope-based (MEBDB) from region differentiation antigens using...

10.1097/id9.0000000000000104 article EN cc-by-nc-nd Infectious Diseases & Immunity 2024-01-01

Abstract Tuberculosis (TB) is an infectious disease that significantly threatens human health. However, the differential diagnosis of latent tuberculosis infection (LTBI) and active (ATB) remains a challenge for clinicians in early detection preventive intervention. In this study, we developed novel biomarker named HP16118P, utilizing 16 helper T lymphocyte (HTL) epitopes, 11 cytotoxic (CTL) 8 B cell epitopes identified from 15 antigens associated with LTBI-RD using IEDB database. We...

10.1186/s43556-024-00177-z article EN cc-by Molecular Biomedicine 2024-04-29

Latent tuberculosis infection (LTBI) is the primary source of active (ATB), but there are no specific methods for diagnosing and preventing LTBI.Dominant T B cell epitopes predicted from five antigens related to LTBI Mycobacterium region difference (LTBI-RD) were used construct a novel polypeptide molecule (PPM). Then, physicochemical properties, secondary structure, tertiary structure PPM, its binding ability toll-like receptor 2 (TLR2) TLR4 analyzed by bioinformatics tools. Finally, immune...

10.3389/fmicb.2022.947852 article EN cc-by Frontiers in Microbiology 2022-06-28

(1) Background: Many co-infections of Mycobacterium tuberculosis (MTB) and severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) have emerged since the occurrence SARS-CoV-2 pandemic. This study aims to design an effective preventive multi-epitope vaccine against co-infection MTB SARS-CoV-2. (2) Methods: The three selected proteins (spike protein, diacylglycerol acyltransferase, low molecular weight T-cell antigen TB8.4) were predicted using bioinformatics, 16 epitopes with highest...

10.3390/jpm13010116 article EN Journal of Personalized Medicine 2023-01-05

Tuberculosis (TB) is an old infectious disease caused by Mycobacterium tuberculosis infection. Vaccination the most effective way to prevent and control TB. However, there relatively little literature that systematically analyzes progress of new TB vaccine research from a bibliometric perspective. This study was conducted examine development vaccines over past 20 years identify priorities directions for future.The Science Citation Index Expanded (SCI-E) Web Core Collection (WOSCC) database...

10.3390/jpm13030408 article EN Journal of Personalized Medicine 2023-02-24

The clinical features and genetics of Rett syndrome (RTT) have been well studied, but examination quality life (QOL) is limited. This study describes the impact severity on QOL among female children adolescents with classic RTT.Cross-sectional longitudinal analyses were conducted data collected from an NIH-sponsored RTT natural history study. More than 200 participants 5 to 18 years age finished their 2-year follow-up at time analysis. Regression models after adjustment for MECP2 mutation...

10.1212/wnl.0b013e3182377dd2 article EN Neurology 2011-10-20

Background Our previous study developed a novel peptide-based vaccine, MP3RT, to fight against tuberculosis (TB) infection in mouse model. However, the consistency between immunoinformatics predictions and results of real-world animal experiments on MP3RT vaccine remains unclear. Method In this study, we predicted antigenicity, immunogenicity, physicochemical parameters, secondary structure, tertiary structure using bioinformatics technologies. The immune response properties were then...

10.3389/fcimb.2022.1047306 article EN cc-by Frontiers in Cellular and Infection Microbiology 2022-11-02

Introduction The Bacillus Calmette-Guérin (BCG) vaccine, currently used against tuberculosis (TB), exhibits inconsistent efficacy, highlighting the need for more potent TB vaccines. Materials and methods In this study, we employed reverse vaccinology techniques to develop a promising multi-epitope vaccine (MEV) candidate, called PP13138R, prevention. PP13138R comprises 34 epitopes, including B-cell, cytotoxic T lymphocyte, helper lymphocyte epitopes. Using bioinformatics immunoinformatics...

10.3389/fimmu.2023.1280299 article EN cc-by Frontiers in Immunology 2023-11-02

OPINION article Front. Immunol., 08 July 2022Sec. Vaccines and Molecular Therapeutics Volume 13 - 2022 | https://doi.org/10.3389/fimmu.2022.953228

10.3389/fimmu.2022.953228 article EN cc-by Frontiers in Immunology 2022-07-08

Abstract Background Latent tuberculosis infection (LTBI) often progresses to active tuberculosis, necessitating the development of novel vaccine prevent LTBI. In this study, we aimed design a Mycobacterium ( M. ) that could elicit potent immune response Methods We used bioinformatics and immunoinformatics techniques develop multi‐epitope (MEV) called C624P. The contained six cytotoxic T lymphocytes (CTL), two helper (HTL), four B‐cell epitopes derived from antigens associated with LTBI...

10.1002/med4.40 article EN cc-by-nc Medicine Advances 2023-11-14

We introduce an intrapericardial control technique using a robotic approach in the surgical treatment of renal tumor with level IV inferior vena cava thrombus to decrease severe complications associated cardiopulmonary bypass and deep hypothermic circulatory arrest.Eight patients thrombi not extending into atrium underwent transabdominal-transdiaphragmatic robot-assisted thrombectomy obviating bypass/deep arrest (cardiopulmonary bypass-free group) by expert team comprising urological,...

10.1097/ju.0000000000002952 article EN The Journal of Urology 2022-10-04

A prospective sonographic study of 40 patients with symptomatic parotid masses detected all their 48 lesions (sensitivity 100%). Computed tomography (CT) 47 97.5%). Ultrasound correctly characterized benign tumours and inflammatory four out five malignant tumours. Deep compartment involvement was accurately delineated in 10 (25%) but two the extraparotid tumour origin could only be by CT. is a sensitive, non-invasive investigation masses. or magnetic resonance should reserved for that...

10.1111/j.1440-1673.1993.tb00049.x article EN Journal of Medical Imaging and Radiation Oncology 1993-05-01

Objective: Factors influencing chronic rhinosinusitis (CRS) are usually studied in terms of genetics and environment; however, clinical indicators have not been reported. This case-control study was conducted Ningbo, China, to explore new independent risk factors for CRS. Methods: A total 695 participants, including 440 healthy controls 255 patients with CRS, were included this study. Clinical data retrieved from questionnaires electronic medical record systems hospitals. Independent...

10.1177/01455613241272475 article EN cc-by-nc Ear Nose & Throat Journal 2024-08-30

Abstract: Forty‐four previously untreated Chinese adult patients with acute lymphoblastic leukemia (ALL) were treated vincristine, adriamycin and prednisone or without L‐asparaginase. The clinical features prognostic factors similar to those reported in Caucasian series. Overall complete remission (CR) rate was 52%. Duration of first overall median survival nine 12 months respectively. addition L‐asparaginase did not improve CR duration associated clotting dysfunction other adverse...

10.1111/j.1445-5994.1989.tb01672.x article EN Australian and New Zealand Journal of Medicine 1989-02-01
Coming Soon ...